Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat
- Development stage
- Unknown
- Lead developer
- Mallinckrodt
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat) is a bioengineered, allogeneic cellularized skin substitute developed by Stratatech, a subsidiary of Mallinckrodt Pharmaceuticals. It is designed as a living tissue construct to treat severe burns, specifically deep partial-thickness thermal burns, by providing a scaffold and active biological components that promote wound closure and reduce the need for autografting (harvesting the patient's own healthy skin). The product consists of two layers: a dermal-like layer containing human dermal fibroblasts and an epidermal-like layer containing human keratinocytes, both seeded onto a scaffold of murine Type I collagen. StrataGraft was approved by the FDA in June 2021 for the treatment of adult patients with deep partial-thickness burns and has been developed with significant support from the Biomedical Advanced Research and Development Authority (BARDA) as a medical countermeasure for mass casualty events.
- Brand names
- StrataGraft
- Other names
- StrataGraft skin tissueStrataGraft constructAllogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
Beyond the preview
Go deeper on allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat.